Management of Mannitol in Hemorrhagic Stroke

Monitoring Parameters for Mannitol Discontinuation

Mannitol should be discontinued in hemorrhagic stroke patients when serum osmolality exceeds 320 mOsm/L, after 2-4 doses (maximum 2 g/kg total), or when there is no clinical improvement in neurological status despite treatment 1, 2, 3
Stop mannitol when serum osmolality exceeds 320 mOsm/L to prevent adverse effects 2, 3
Discontinue if the patient shows clinical deterioration despite treatment 3
Consider stopping if the patient has achieved sustained neurological improvement and stable ICP 1

Mannitol's maximum effect is observed after 10-15 minutes and typically lasts for 2-4 hours, requiring reassessment after this period 3

Consider surgical decompression (hemicraniectomy) as a more definitive treatment for massive cerebral edema when medical management fails 4, 1
Hypertonic saline (3% or 23.4%) may be an alternative to mannitol and may have a longer duration of action in some cases 3
For large hemispheric hemorrhages where herniation is the main concern rather than generalized increased ICP, surgical intervention may be more appropriate than continued osmotic therapy 4, 1

Prophylactic administration of mannitol is not recommended in hemorrhagic stroke patients without evidence of increased ICP 3
Despite its widespread use, a Cochrane systematic review found no evidence that routine use of mannitol reduced cerebral edema or improved stroke outcomes 1
Non-pharmacological measures should be maintained throughout treatment, including head elevation at 20-30°, neutral neck position, and avoidance of factors that could exacerbate swelling (hypoxemia, hypercarbia, hyperthermia) 4, 5

Administer 3 % NaCl in 4–6 hour intervals during active treatment of elevated intracranial pressure in stroke patients【6】.

At approximately 250 mOsm (equiosmolar dosing), mannitol and hypertonic saline provide similar reductions in intracranial pressure, indicating comparable efficacy for ICP control【6】.